703 results match your criteria Surveillance for Recurrent Bladder Cancer


A case of a unique presentation of a primary vaginal endometrioid adenocarcinoma arising in the setting of a recurrent peritoneal inclusion cyst fistulized to the vagina.

Gynecol Oncol Rep 2020 Aug 16;33:100585. Epub 2020 May 16.

University of Cincinnati Department of Obstetrics & Gynecology: Division of Gynecologic Oncology, 234 Goodman Street, Cincinnati, OH 45219, USA.

Primary vaginal endometrioid adenocarcinoma is a rare cancer that is often associated with chronic endometriosis. We present the case of a 72-year-old female who underwent right salpingo-oophorectomy followed by hysterectomy with benign pathology 25 years prior to her cancer diagnosis. She had an extensive surgical history in the intervening years and several complicating factors including a history of endometriosis as well as a recurrent peritoneal inclusion cyst treated with ethanol sclerotherapy, followed by formation of a peritoneal-vaginal fistula. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2020.100585DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243260PMC

Recurrent Bladder Cancer in a Teenage Male.

Urology 2020 Apr 22. Epub 2020 Apr 22.

Department of Urology, University of Kentucky, Lexington, KY. Electronic address:

Urothelial cell carcinoma of the bladder is exceedingly rare in pediatric patients. Based on current literature, bladder cancer in this population is thought to be low-grade, noninvasive, and unlikely to recur, suggesting significant biologic differences when compared to the adult population. This is a 15-year-old male diagnosed with low-grade urothelial cell carcinoma with subsequent multifocal recurrence on surveillance cystoscopy managed by induction and maintenance intravesical Bacillus Calmette-Guerin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.04.031DOI Listing

Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Non Muscle Invasive Bladder Cancer Follow up: A Blinded, Prospective Cohort, Multicentric European Study.

J Urol 2020 Apr 21:101097JU0000000000001084. Epub 2020 Apr 21.

Fundacio Puigvert, Dept of Urology, Barcelona, Spain.

Purpose: Detection of MCM5 containing cells in urine has been shown to be indicative for the presence of a bladder tumour in primary diagnosis. The objective of this study was to evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in Non Muscle Invasive Bladder Cancer (NMIBC) follow-up.

Materials And Methods: A multicentric prospective blinded study was carried out at 21 European centres in patients undergoing cystoscopy for NMIBC surveillance, diagnosed in the preceding 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000001084DOI Listing

Developments in the follow-up of nonmuscle invasive bladder cancer: what did we learn in the last 24 months: a critical review.

Authors:
J Alfred Witjes

Curr Opin Urol 2020 May;30(3):387-391

Department of Urology, Radboudumc Nijmegen, Nijmegen, The Netherlands.

Purpose Of Review: Patients with nonmuscle invasive bladder cancer (NMIBC) have a high risk of recurrent tumors, even in spite of contemporary guideline recommended therapy. Follow-up recommendations are also clear (cystoscopy with cytology and upper urinary tract imaging in high-risk patients), but frequency and duration of follow-up are well defined. However, recent developments in follow-up tools might be of interest for clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000741DOI Listing

An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer.

BMC Urol 2020 Feb 11;20(1):12. Epub 2020 Feb 11.

Capital & Coast District Health Board, Wellington, New Zealand.

Background: Surveilling recurrent urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during post-treatment surveillance.

Objective: To audit the clinical utility of a new surveillance protocol incorporating the Cxbladder Monitor (CxbM) test in real-world practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-020-0583-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014779PMC
February 2020

Bladder cancer trends and mortality in the brazilian public health system.

Int Braz J Urol 2020 Mar-Apr;46(2):224-233

Disciplina de Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil.

Introduction: Considering the lack of data on BC trends in Brazilian population, mainly as a result of the difficulty on gathering data, the present manuscript provides an overview of bladder cancer incidence, hospitalization, mortality patterns and trends using the Brazilian Data Center for The Public Health System (DATASUS).

Materials And Methods: All hospital admissions associated with BC diagnosis (ICD-10 C67) between 2008 and 2017 were analyzed. Distributions according to year, gender, age group, ethnicity, death, length of hospital stay, and costs were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2019.0198DOI Listing

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

J Urol 2020 05 10;203(5):902-909. Epub 2019 Dec 10.

Department of Urology, University of Iowa, Iowa City, Iowa.

Purpose: Rescue intravesical therapies for patients with bacillus Calmette-Guérin failure nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel therapy has shown safety and efficacy in 2 retrospective, single institution cohorts. This doublet has since been adopted as an intravesical salvage option at multiple institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000688DOI Listing

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.

Int J Clin Oncol 2020 Jan 15;25(1):165-174. Epub 2019 Nov 15.

PSMAR-IMIM Research Institute, Carrer del Dr. Aiguader, 88, Barcelona, Spain.

Background: The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy, compared with standard chemotherapy (paclitaxel, docetaxel, or vinflunine). Pembrolizumab is approved for patients with bladder cancer in Japan.

Patients And Methods: Analysis was performed in the subgroup of Japanese patients enrolled in the KEYNOTE-045 study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01545-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946746PMC
January 2020

Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project.

World J Urol 2019 Nov 5. Epub 2019 Nov 5.

Department of Urology, Istituto Clinico Humanitas IRCCS-Clinical and Research Hospital, via Manzoni 56, 20089, Milan, Rozzano, Italy.

Purpose: To investigate the clinical performance of a new mRNA-based urine test, aiming to avoid unnecessary follow-up cystoscopy in patients under active surveillance (AS) for recurrent NMIBC.

Methods: This is a prospective cohort study enrolling patients with history of low-grade (LG) NMIBC, who developed a recurrence during the follow-up and underwent AS. Their urinary samples were analyzed by Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-03002-3DOI Listing
November 2019
2.666 Impact Factor

Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile.

Diagn Pathol 2019 Oct 21;14(1):113. Epub 2019 Oct 21.

Department of Pathology, University of Michigan Medical School, 2800 Plymouth Rd, Building 35, Ann Arbor, MI, 48109, USA.

Background: Rapid ("warm") autopsies of patients with advanced metastatic cancer provide important insight into the natural history, pathobiology and histomorphology of disease in treatment-resistant tumors. Plasmacytoid urothelial carcinoma (PUC) is a rare variant of urothelial carcinoma characterized by neoplastic cells morphologically resembling plasma cells. PUC is typically aggressive, high-stage at presentation, and associated with poor outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13000-019-0896-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802321PMC
October 2019
2 Reads

Pelvic Exenteration for Advanced Nonrectal Pelvic Malignancy.

Authors:

Ann Surg 2019 11;270(5):899-905

Objective: To determine factors associated with outcomes following pelvic exenteration for advanced nonrectal pelvic malignancy.

Background: The PelvEx Collaborative provides large volume data from specialist centers to ascertain factors associated with improved outcomes.

Methods: Consecutive patients who underwent pelvic exenteration for nonrectal pelvic malignancy between 2006 and 2017 were identified from 22 tertiary centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000003533DOI Listing
November 2019
4 Reads

The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.

J Urol 2020 02 24;203(2):283-291. Epub 2019 Sep 24.

Department of Urology, Amsterdam University Medical Center, University of Amsterdam, The Netherlands.

Purpose: The objective of this study was to assess the value of fluorescence in situ hybridization to predict early recurrence in patients with nonmuscle invasive bladder cancer at intermediate and high risk treated with bacillus Calmette-Guérin.

Materials And Methods: We performed a systematic review using MEDLINE®, Embase® and the Cochrane Library. Individual patient data from prospective observational studies of fluorescence in situ hybridization in patients treated with bacillus Calmette-Guérin were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000566DOI Listing
February 2020

The impact of age on intravesical instillation of Bacille Calmette-Guerin treatment in patients with high-grade T1 bladder cancer.

Medicine (Baltimore) 2019 Aug;98(31):e16223

Department of Urology and Renal Transplantation.

Intravesical instillation of Bacille Calmette-Guèrin (BCG) is the standard adjuvant treatment for high-risk non muscle invasive bladder cancer (NMIBC). Since its mechanism of action is supposed to be linked to the immune system efficiency and senescence could negatively affect this efficiency, BCG efficacy in the elderly has been questioned. This study aimed to assess the impact of age on BCG efficacy and safety in patients with high-grade T1 bladder cancer (BC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000016223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708772PMC

Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3β signaling.

Cancer Sci 2019 Sep 23;110(9):2822-2833. Epub 2019 Jul 23.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Kinesin family member C1 (KIFC1) is implicated in the clustering of multiple centrosomes to maintain tumor survival and is thought to be an oncogene in several kinds of cancers. In our experiments, we first performed bioinformatics analysis to investigate the expression levels of KIFC1 in bladder cancer (BC) specimens and normal bladder epitheliums and then, using our samples, verified findings by quantitative real-time PCR and western blotting assays. All data showed that KIFC1 was significantly upregulated in BC specimens at both the mRNA and protein levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.14126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726677PMC
September 2019
26 Reads

Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?

Eur Urol Oncol 2019 Nov 22;2(6):723-729. Epub 2019 Jun 22.

Urologic Sciences, The University of British Columbia, Vancouver, Canada.

Recurrent low-grade Ta tumours, classified as intermediate-risk non-muscle-invasive bladder cancer (NMIBC), have a high risk of recurrence but a low risk of progression. This case presents a 60-yr-old female with intermediate-risk NMIBC who has been treated with sequential courses of mitomycin C followed by bacillus Calmette-Guérin (BCG). She continued to develop multiple episodes of recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.003DOI Listing
November 2019
7 Reads

Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma.

Future Oncol 2019 Jul 25;15(19):2267-2275. Epub 2019 Jun 25.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11351, Egypt.

To assess mortality from bladder cancer following a diagnosis of nonmuscle-invasive bladder cancer. This is a SEER registry-based study. The risk of death from bladder cancer was compared with that of the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0861DOI Listing
July 2019
1 Read
2.477 Impact Factor

American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model?

J Urol 2019 10 6;202(4):682-688. Epub 2019 Sep 6.

Department of Urology, School of Medicine and Public Health and Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, Wisconsin.

Purpose: We evaluated the AUA (American Urological Association)/SUO (Society of Urologic Oncology) nonmuscle invasive bladder cancer risk model to predict nonmuscle invasive bladder cancer recurrence and progression prior to death.

Materials And Methods: We performed a retrospective analysis using electronic medical records and cancer registry data of patients with nonmuscle invasive bladder cancer in a multicenter United States patient population. We evaluated recurrence-free and progression-free survival according to the AUA/SUO nonmuscle invasive bladder cancer risk model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000389DOI Listing
October 2019
13 Reads

Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.

Eur Urol Oncol 2018 10 5;1(5):437-442. Epub 2018 Jun 5.

Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Italy.

Background: It has been shown that active surveillance (AS) is feasible and effective in a subset of patients with recurrent low-grade (LG) non-muscle-invasive bladder cancer (NMIBC).

Objective: To update a previous preliminary series and investigate pathological outcomes for patients who failed to remain on AS.

Design, Setting, And Participants: Prospective observational cohort study started in February 2008, and currently still active, at a tertiary university hospital, including patients with pathologically confirmed NMIBC who experienced recurrence during follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.05.006DOI Listing
October 2018
15 Reads

Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes.

BJU Int 2019 11 2;124(5):746-757. Epub 2019 Jul 2.

Department of Urology and Transplantation Surgery, Edouard Herriot Hospital, Lyon, France.

Objectives: To evaluate the oncological and functional outcomes of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after low-dose-rate (LDR) brachytherapy.

Patients And Methods: Clinical phase II studies (2003-2015) included 50 consecutive patients with post-brachytherapy local recurrence treated by S-HIFU. S-HIFU was performed with post-external beam radiotherapy (EBRT) parameters and, since 2008, with specific post-brachytherapy parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14838DOI Listing
November 2019
6 Reads

Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.

Scand J Urol 2019 Apr - Jun;53(2-3):109-115. Epub 2019 May 8.

d Department of Urology , Landspitali University Hospital , Reykjavik , Iceland.

In non-muscle-invasive bladder cancer (NMIBC), local recurrence after transurethral resection of the bladder (TURB) is common. Outcomes vary between urological centres, partly due to the sub-optimal surgical technique and insufficient application of measures recommended in the guidelines. This study evaluated early recurrence rates after primary TURB for NMIBC before and after introducing a standardized treatment protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21681805.2019.1604568DOI Listing
January 2020
1 Read

Active surveillance for non-muscle invasive bladder cancer.

Transl Androl Urol 2019 Feb;8(1):54-60

Department of Urology, Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris Descartes University, Paris, France.

Most of low grade (LG) bladder tumors will experience disease recurrence and very few of them (<2%) will experience disease progression. Therefore active surveillance (AS) for LG non-muscle invasive bladder cancer (NMIBC) has emerged. The goal of our study was to provide a literature review of AS for LG NMIBC including inclusion criteria, modalities and oncological outcomes. Read More

View Article

Download full-text PDF

Source
http://tau.amegroups.com/article/view/22272/22811
Publisher Site
http://dx.doi.org/10.21037/tau.2018.10.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414342PMC
February 2019
18 Reads

APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.

Eur Urol 2019 07 8;76(1):9-13. Epub 2019 Apr 8.

Institut Curie, CNRS, UMR144, Molecular Oncology team, PSL Research University, Paris, France. Electronic address:

FGFR3 is one of the most frequently mutated genes in bladder cancer and a driver of an oncogenic dependency. Here we report that only the most common recurrent FGFR3 mutation, S249C (TCC→TGC), represents an APOBEC-type motif and is probably caused by the APOBEC-mediated mutagenic process, accounting for its over-representation. We observed significant enrichment of the APOBEC mutational signature and overexpression of AID/APOBEC gene family members in bladder tumors with S249C compared to tumors with other recurrent FGFR3 mutations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.032DOI Listing
July 2019
6 Reads

Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.

Int J Surg Pathol 2019 Aug 11;27(5):483-491. Epub 2019 Mar 11.

1 Clinical Research and Practical Center for Specialized Oncological Care, Saint Petersburg, Russia.

Urothelial cancer is a heterogeneous disease with different molecular pathways that produce distinct molecular subtypes with specific characteristics and patient survival outcomes that require different therapeutic methods. Urothelial tumors in young patients appear to have distinct genetic features compared with their counterparts in older patients. Using a Lund subtype-specific immunohistochemistry panel, we performed molecular subtype profiling of an urothelial carcinoma case series (n = 49) in patients younger than 45 years of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1066896919830509DOI Listing

Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory.

Support Care Cancer 2019 Oct 14;27(10):3877-3885. Epub 2019 Feb 14.

Cancer Rehabilitation and Survivorship Program, Princess Margaret Cancer Centre, Toronto, Canada.

Background: To date, little research has examined the quality of life and cancer-associated needs of bladder cancer patients. The objective of the current study was to assess the quality of life (QoL), informational needs, and supportive care needs (SCN) in a large sample of muscle invasive (MIBC) and non-muscle invasive (NMIBC) bladder cancer survivors across the treatment trajectory (newly diagnosed and undergoing treatment, post-treatment follow-up, and treatment for advanced/recurrent disease).

Methods: Questionnaires were distributed to a convenience sample of patients registered with Bladder Cancer Canada, the Princess Margaret Cancer Centre, or The Ottawa Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-4649-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726665PMC
October 2019
6 Reads

MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.

Cancer Epidemiol Biomarkers Prev 2019 04 30;28(4):782-788. Epub 2019 Jan 30.

Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Background: The high rate of non-muscle-invasive bladder cancer recurrence is a major challenge in patient management. miRNAs functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers because they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle-invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-0884DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473178PMC
April 2019
4 Reads
4.125 Impact Factor

Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.

BJU Int 2019 06 5;123(6):959-967. Epub 2019 Feb 5.

Department of Urology, Medical University of Vienna, Vienna, Austria.

Objectives: To investigate prospectively the clinical utility and influence on decision-making of Bladder EpiCheck™, a non-invasive urine test, in the surveillance of non-muscle-invasive bladder cancer (NMIBC).

Materials And Methods: Urine samples from 440 patients undergoing surveillance for NMIBC were prospectively collected at five centres and evaluated using the Bladder EpiCheck test (NCT02647112). A multivariable nomogram and decision-curve analysis (DCA) were used to evaluate the impact of Bladder EpiCheck on decision-making when used in routine clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850401PMC
June 2019
5 Reads

Recurrent activating mutations of PPARγ associated with luminal bladder tumors.

Nat Commun 2019 01 16;10(1):253. Epub 2019 Jan 16.

Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue contre le Cancer, 75005, Paris, France.

The upregulation of PPARγ/RXRα transcriptional activity has emerged as a key event in luminal bladder tumors. It renders tumor cell growth PPARγ-dependent and modulates the tumor microenvironment to favor escape from immuno-surveillance. The activation of the pathway has been linked to PPARG gains/amplifications resulting in PPARγ overexpression and to recurrent activating point mutations of RXRα. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-08157-y
Publisher Site
http://dx.doi.org/10.1038/s41467-018-08157-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335423PMC
January 2019
37 Reads

Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer.

Proteomics Clin Appl 2019 03 30;13(2):e1800148. Epub 2019 Jan 30.

Proteomics Laboratory, Biotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.

Purpose: To evaluate the diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) in detecting urinary bladder cancer (UBC).

Methods: The Integrated Study on Bladder Cancer (n = 571; mean age:69.4 ± 12. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/prca.201800148
Publisher Site
http://dx.doi.org/10.1002/prca.201800148DOI Listing
March 2019
7 Reads

Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report.

J Ovarian Res 2019 Jan 10;12(1). Epub 2019 Jan 10.

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, 201, Section 2, Shih-Pai Road, Taipei, 112, Taiwan, Republic of China.

Background: The value of this report is the identification of late recurrence with an extremely unusual combination of malignant transformation. In particular, the retroconversion of immature to mature teratoma as well as a somatic-type malignant transformation were both observed postchemotherapeutically in our case.

Case Presentation: We report the case of a 20-year-old girl who completed fertility-sparing surgery and chemotherapy under the diagnosis of ovarian mixed germ cell tumor (immature teratoma and yolk sac tumor) and experienced subsequent recurrence 4 years after a second debulking surgery with a somatic type malignant transformation (teratoma with melanoma and leiomyosarcoma). Read More

View Article

Download full-text PDF

Source
https://ovarianresearch.biomedcentral.com/articles/10.1186/s
Publisher Site
http://dx.doi.org/10.1186/s13048-018-0476-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327407PMC
January 2019
29 Reads

Preneoplastic Lesion in a Pancreas Allograft: Dilemma for the Pancreas Transplant Surgeon.

Transplant Proc 2018 Dec 30;50(10):3694-3697. Epub 2018 Jun 30.

Division of Transplantation, Department of Surgery, University of Minnesota Medical School, Minneapolis, MN.

Although the relationship between immunosuppression and cancer risk is well-documented, the association between immunosuppression and the development of preneoplastic lesions (PNL) is less clear. PNLs pose a unique clinical conundrum in the transplanted pancreas because their prevalence in the general population is not infrequent. We present the case of a 58-year-old man with a history of diabetes mellitus type 1 who underwent successful pancreas transplantation with bladder drainage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.06.047DOI Listing
December 2018
3 Reads

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Eur Urol 2019 05 12;75(5):853-860. Epub 2018 Dec 12.

Radboudumc, Nijmegen, The Netherlands.

Background: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC.

Objective: To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.11.055DOI Listing
May 2019
7 Reads

Reduced Recurrence of Low-grade Papillary Bladder Tumors Associated With Asymptomatic Bacteriuria.

Urology 2019 02 23;124:179-182. Epub 2018 Oct 23.

Urology Service, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Objective: To determine tumor recurrence rate of low-grade, papillary, and non-muscle-invasive (TaLG) bladder tumors in patients who have asymptomatic bacteriuria (ABU). Microbes in the urine trigger immune responses like intravesical Bacillus Calmette-Guerin, suggesting that common bacteria may also exert an antitumor effect.

Methods: We investigated recurrence rates in 387 patients with low-grade, papillary noninvasive bladder tumors TaLG, with or without ABU. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00904295183110
Publisher Site
http://dx.doi.org/10.1016/j.urology.2018.10.023DOI Listing
February 2019
18 Reads

Micronuclei frequency in urothelial cells of bladder cancer patients, as a biomarker of prognosis.

Environ Mol Mutagen 2019 03 4;60(2):168-173. Epub 2018 Oct 4.

Grup de Mutagènesi, Departament de Genètica i de Microbiologia, Facultat de Biociències, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08193, Barcelona, Spain.

It has been suggested that the frequency of micronuclei (MN) in defoliated urothelial cells could be used as a biomarker for both the potential risk of bladder cancer (BC) and its progression. To prove this we have carried out a large study evaluating the MN frequency in a group of 383 hospital patients submitted to cystoscopy. From them, 77 were negative in their first cystoscopy, and were considered as a reference group; 79 were positive and were classified as patients with tumor; and 227 with previous bladder cancer submitted to follow-up monitoring were negative and classified as BC patients without tumor. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/em.22252
Publisher Site
http://dx.doi.org/10.1002/em.22252DOI Listing
March 2019
12 Reads

The conundrum of recurrent low-grade tumours: to treat or to observe?

Curr Opin Urol 2018 11;28(6):557-562

Department of urology, University of Rochester School of Medicine, Rochester, New York, USA.

Purpose Of Review: To describe the importance of risk stratification and the role of more conservative management like office fulguration, office laser ablation and active surveillance in recurrent low-grade Ta tumours.

Recent Findings: Updated models have been designed for risk stratification of intermediate-risk tumours. Conservative forms of management like office fulguration or laser ablation and even active surveillance seem well tolerated; however, randomized, controlled trials are lacking. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00042307-900000000-9916
Publisher Site
http://dx.doi.org/10.1097/MOU.0000000000000550DOI Listing
November 2018
4 Reads

Case 258: Granulomatous Prostatitis.

Radiology 2018 10;289(1):267-271

From the Departments of Radiology (A.D.d.L., D.N.C., I.P.), Urology (I.P.), and Pathology (F.F.), and the Advanced Imaging Research Center (D.N.C., I.P.), University of Texas Southwestern Medical Center, 2201 Inwood Rd, 2nd Floor, Suite 202, Dallas, TX 75390-9085.

History A 68-year-old man with a remote history of a previously resected high-grade urothelial carcinoma in the renal pelvis was being observed and was undergoing urologic treatment for recurrent low-grade urothelial carcinoma of the bladder. During his most recent evaluation, he reported no specific symptoms and denied experiencing hematuria, dysuria, or abdominal pain. At routine surveillance MRI of the abdomen and pelvis (images not shown), a lesion was noted in the peripheral zone of the prostate gland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018161272DOI Listing
October 2018
24 Reads

Recurrent Urinary Tract Infections in Females and the Overlap with Overactive Bladder.

Curr Urol Rep 2018 Sep 13;19(11):94. Epub 2018 Sep 13.

Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Purpose Of Review: There are an estimated 33 million men and women with overactive bladder (OAB) in the USA. Despite the prevalence of OAB, it remains a frequently misdiagnosed condition. OAB has shared symptomatology with other common urologic conditions, namely recurrent urinary tract infections (UTIs). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11934-018-0839-3
Publisher Site
http://dx.doi.org/10.1007/s11934-018-0839-3DOI Listing
September 2018
71 Reads

[ACTIVE SURVEILLANCE IN RECURRENT LOW-RISK BLADDER TUMORS].

Harefuah 2018 Aug;157(8):507-510

Department of Urology, Hadassah Hebrew University Hospital, Jerusalem.

Objectives: To report our experience with the active surveillance policy in patients with recurrent low-risk bladder tumors.

Methods: The files of 52 patients who underwent active surveillance instead of immediate surgical resection were reviewed. Different variables concerning tumor growth rate were evaluated. Read More

View Article

Download full-text PDF

Source
August 2018
6 Reads

Risk of ESRD and Mortality in Kidney and Bladder Stone Formers.

Am J Kidney Dis 2018 12 23;72(6):790-797. Epub 2018 Aug 23.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. Electronic address:

Rationale & Objectives: Kidney stones have been associated with increased risk for end-stage renal disease (ESRD). However, it is unclear whether there is also an increased risk for mortality and if these risks are uniform across clinically distinct categories of stone formers.

Study Design: Historical matched-cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2018.06.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252145PMC
December 2018
7 Reads

Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.

Cell Physiol Biochem 2018 16;48(6):2364-2373. Epub 2018 Aug 16.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Background/aims: This study aimed to validate the value of urothelial stem cell (USC) markers ΔNp63, integrin β4, CD47, and CD44v6 in predicting the prognosis of non-muscle invasive bladder cancer (NMIBC) located in different anatomic regions of bladder.

Methods: The study reviewed the clinicopathologic data of 169 patients with NMIBC. Using real-time PCR and immunohistochemistry, the expression of ΔNp63, integrin β4, CD47, and CD44v6 in archived specimens of patients with NMIBC were validated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492652DOI Listing
September 2018
10 Reads
2.880 Impact Factor

Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study.

Bladder Cancer 2018 Jul 30;4(3):303-310. Epub 2018 Jul 30.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Objectives: To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence.

Study Design: Prospective cohort study.

Methods: 716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-180172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087451PMC
July 2018
9 Reads

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

World J Urol 2019 Jan 14;37(1):51-60. Epub 2018 Aug 14.

Division of Urology, McGill University Health Center-Glen Site, 1001 Decarie Blvd, Montreal, QC, H3A 3J1, Canada.

Purpose: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC).

Methods: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-018-2438-9DOI Listing
January 2019
57 Reads

Ureteral pseudodiverticulosis and urothelial cell carcinoma: rethinking the association.

Abdom Radiol (NY) 2019 01;44(1):234-238

Department of Radiology, University of Pennsylvania, 3400 Spruce Street, 1 Silverstein, Philadelphia, PA, 19104, USA.

Purpose: To compare frequency of new and recurrent urothelial cell carcinoma (UCC) among patients with and without pseudodiverticulosis on imaging.

Methods: This retrospective case-control study compared all 113 sequential patients with ureteral pseudodiverticulosis on radiographic urography between 1/1/2002 and 12/31/2012. Six patients were lost to follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-018-1726-6DOI Listing
January 2019
35 Reads

Colovesical fistula: review on conservative management, surgical techniques and minimally invasive approaches.

G Chir 2018 Jul-Aug;39(4):195-207

Colovesical fistula (CVF) is an abnormal communication between bowel and urinary bladder. Main causes are represented by complicated diverticular disease, colonic and bladder cancer and iatrogenic complications. Diagnosis is often based on patognomonic signs: faecaluria, pneumaturia and recurrent urinary tract infections. Read More

View Article

Download full-text PDF

Source
September 2019
1 Read

Novel therapies in urothelial carcinoma: a biomarker-driven approach.

Ann Oncol 2018 12;29(12):2302-2312

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis comprised ∼8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of patients exhibit long-term survival following cisplatin-based chemotherapy and in patients with recurrent disease, response rates to second-line chemotherapy are generally 15%-20% with a 3-month progression-free survival. However, recent advances in immunotherapy represent an opportunity to significantly improve patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdy254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887951PMC
December 2018
1 Read

Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.

Am J Surg Pathol 2018 10;42(10):1286-1296

Department of Pathology, Johns Hopkins Medical Institute, Baltimore, MD.

Prostatic adenocarcinoma with focal pleomorphic giant cell features is rare with the only prior series consisting of 6 cases. From 2005 to 2018, we identified 29 cases from our consult service and 1 case from our own institution. Men ranged in age from 39 to 90 years (median=75. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001112DOI Listing
October 2018
11 Reads

An unusual diverticulum adjacent to two large colonic polyps; a case report.

BMC Gastroenterol 2018 Jun 14;18(1):83. Epub 2018 Jun 14.

Department of Gastroenterology, Sheffield Teaching Hospitals, Northern General Hospital, Herries Road, Sheffield, S5 7AU, England.

Background: Adenocarcinomas can arise in a variety of circumstances in which intestinal segments have been used for urinary diversions. Whereas ureterosigmoidostomy is the oldest and simplest form of continent urinary diversion it also seems to be the most dangerous in this regard. Herein we present a case of colonic neoplasia complicating a non-functioning ureterosigmoidostomy after 55 years; the longest latent period documented to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12876-018-0816-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001174PMC
June 2018
10 Reads

Bladder cancer in nonagenarians: a multicentre study of 123 patients.

BJU Int 2018 12 26;122(6):1010-1015. Epub 2018 Jul 26.

Department of Urology, Kaiser-Franz-Josef-Spital, Vienna, Austria.

Objective: To investigate the oncological outcome of nonagenarians with bladder cancer, as a substantial rise in bladder cancer in the old-old age group in the upcoming decades is expected, due to demographic changes and the peak incidence around the age of 85 years. The paucity of data of nonagenarians prompted us to investigate the outcomes of such patients.

Patients And Methods: A retrospective, multicentre study was designed to assess patient demographics, tumour patterns, treatment strategies and outcome in patients aged ≥90 years treated at participating centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14419DOI Listing
December 2018
13 Reads

Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases.

Am J Surg Pathol 2018 07;42(7):971-976

Departments of Pathology.

Urothelial carcinoma in situ (CIS) of the bladder with glandular differentiation (CIS-GL) is rare with some showing an association with small cell carcinoma. There is a paucity of data on whether CIS-GL diagnosed in the absence of invasive carcinoma is associated with an increased risk of developing small cell carcinoma of the bladder. Twenty-seven cases of CIS-GL were identified from the consult files of one of the authors from 2008 to 2015 without prior or coexisting invasive carcinoma at the time of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001073DOI Listing
July 2018
8 Reads

Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study.

Cancer Causes Control 2018 06 17;29(6):573-579. Epub 2018 Apr 17.

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

Introduction: There is some evidence that greater consumption of fruit and vegetables decreases the risk of bladder cancer. The role of fruit and vegetables in bladder cancer recurrence is still unknown.

Objective: The role of total fruit and vegetable intake in relation to the risk of developing bladder cancer recurrence in a prospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-018-1029-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938309PMC
June 2018
32 Reads